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Abstract: Marine environments are underexplored terrains containing fungi that produce a diversity
of natural products given unique environmental pressures and nutrients. While bacteria are commonly the most studied microorganism for natural products in the marine world, marine fungi are
also abundant but remain an untapped source of bioactive metabolites. Given that their terrestrial
counterparts have been a source of many blockbuster antitumor agents and anti-infectives, including
camptothecin, the penicillins, and cyclosporin A, marine fungi also have the potential to produce new
chemical scaffolds as leads to potential drugs. Fungi are more phylogenetically diverse than bacteria
and have larger genomes that contain many silent biosynthetic gene clusters involved in making
bioactive compounds. However, less than 5% of all known fungi have been cultivated under standard
laboratory conditions. While the number of reported natural products from marine fungi is steadily
increasing, their number is still significantly lower compared to those reported from their bacterial
counterparts. Herein, we discuss many varied cytotoxic and anti-infective fungal metabolites isolated
from extreme marine environments, including symbiotic associations as well as extreme pressures,
temperatures, salinity, and light. We also discuss cultivation strategies that can be used to produce
new bioactive metabolites or increase their production. This review presents a large number of
reported structures though, at times, only a few of a large number of related structures are shown.
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Natural products have been a rich source of therapeutics since the beginning of
civilization. To date, ~60% of all small-molecule drugs approved by the US Food and
Drug Administration (FDA), or their equivalent in other countries, have been inspired
by these secondary metabolites [1]. Many are anti-infectives and antitumor agents that
have been isolated from microbes, including those with symbiotic associations. While
microbes are a prolific source of bioactive molecules used to treat cancer and infectious
diseases, chemists have been repetitively rediscovering natural products, thus leading to
the requirement for a system for the rapid dereplication of known compounds and/or their
close relatives. Microbes usually express fewer biosynthetic gene clusters (BGCs) when
grown under standard laboratory conditions, even though they have the genetic potential
to express more secondary metabolic BGCs. To circumvent these limitations, scientists
are either cultivating microbes under nominally non-standard laboratory conditions to
activate the expression of cryptic BGCs [2], using genetic engineering and ‘omics methods
to identify and directly express BGCs [3], or they are isolating microbes from understudied
environments [4].
Extreme ecosystems represent new frontiers for drug discovery, as these locations
contain unique environmental variables that are not found in mesophilic locales and
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influence microbial metabolism. Extreme environments have been underexplored due to
the challenges in accessing these locales. However, more sampling tools and techniques
have been developed to study marine environments, presenting new opportunities for
exploration. The marine world is vast, covering ~70% of Earth, including some of the
most extreme ecosystems on the planet. Extreme marine environments are characterized
as having high pressures, and temperatures that can range from close to freezing to over
250 ◦ C at the “black smokers”, severe ultraviolet radiation, high salt or metal concentrations,
symbiosis, or more than one combination of these variables. Microbes constitute much
of the biomass in the sea and are prominent producers of secondary metabolites, with a
wide range of potent bioactivities against tumor cells and other pathogens, plus potential
in other diseases. Thus, bioprospecting these environments for new drugs is an attractive
prospect, especially as marine natural products have high hit rates in a broad range of
bioassays, with many in clinical and preclinical trials. For a current assessment, the web
site, www.marinepharmacology.org (accessed on 12 December 2021), is kept up to date,
covering approved drugs from marine sources and compounds that are in clinical trials
from Phase I to Phase III plus selected preclinical candidates. Most of the information is
from the NIH trials database (www.clinicaltrials.gov accessed on 12 December 2021), but it
also includes data from comparable databases from other countries.
Most microbe-derived marine natural products tend to be isolated from bacteria,
which make up much of the biomass in seawater (i.e., >105 cells per milliliter) and are
extremely well represented in deep oceanic “muds”. However, fungi are also abundant,
as 103 to 104 fungal cells are contained in a milliliter of seawater. Approximately 38% of
the reported ~23,000 bioactive microbial metabolites are of fungal origin and only 5% of
the microbial taxa had been identified as of 2008, 10% of which are fungi [5]. Fungi have
larger genomes with more BGCs, resulting in greater chemodiversity [6,7]. Furthermore,
they have produced numerous clinically approved anti-infectives and antitumor drugs, as
mentioned earlier, but remain understudied.
Why are there disparities in the isolation of marine natural products from fungi? While
genetic engineering and ‘omics methods are being used to isolate an increasing amount
of bacterial natural products, these methods are still in their infancy insofar as fungi are
concerned. Cultivation which is still one of the main ways to discover bioactive metabolites
continues to be a challenge when working with marine fungi. Scientists are still using
antiquated methods that promote the growth of generalist genera, such as Penicillium and
Aspergillus to culture marine fungi [8]. In 2019, we published a compendium of bioactive
compounds isolated from marine fungi [9]. Herein, we update that list, focusing on antiinfective and antitumor agents as well as other fungal natural products with potential from
marine environments. This review aims to highlight the bioactive metabolites found from
culturable fungi isolated from marine environments and cultivation methods that have
been found to increase the production of diverse bioactive metabolites.
Although we are listing significant numbers of compounds (approximately 200) in
this review, we will only show the structures of compounds for which biological activities
have been reported and will give the names of the others with suitable references, so that
readers may consult the original literature for related compounds without a biological
activity reported at that time.
1.1. Antitumor Agents from Deep-Sea Sediments
It should be mentioned at this point that it was well known in the early days of
antimicrobial assays, though never formally reported from the pharmaceutical industry,
that compounds with antitumor activities in vitro also inhibited Gram-positive bacteria
at comparable concentrations in disc diffusion assays (DJN Personal Observations). The
following examples will be arranged as best we can, by the area(s) from which the sediments
were collected for subsequent isolation of fungi.
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1.2. Indian Ocean
Numerous potential antitumor agents (some also with antibacterial activity) continue
to be isolated and reported from deep-sea-derived fungi collected from the Indian Ocean.
The new diterpenoids, longidiacids A (1) and B, polyketides, and the cytochalasin analogs,
longichalasins A and B (2), were isolated from the fungus Diaporthe longicolla FS429 [10]
obtained from deep-sea sediment collected at a depth of 3000 m. Longidiacid A (1) and
longichalasin B (2) inhibited tyrosine phosphatase B in Mycobacterium tuberculosis cells by
35.4% and 53.5%, respectively, and longichalasin B (2) exhibited antiproliferative activity
against glioblastoma cells (SF-268) with an IC50 value of 16.44 µM.
From sediment collected at a depth of 3471 m, the fungus Cladosporium cladosporiodes
HDN14-342 yielded the polyketides, clindanones A and B as well as cladosporols F and G
(3, 4) following cultivation [11]. Cladosporols F and G exhibited cytotoxic activities against
the human cervical (HeLa), leukemia (K562), and colon (HCT-116) cancer cells with IC50
values ranging from 3.9 to 23.0 µM depending upon the particular cell line. In 2017, Li et al.
published revisions of the initial structures of these two metabolites [12].
Phomopsis lithocarpus FS508 was isolated from a sediment sample collected at 3606 m
and fermented, producing several benzophenone aldehydes, including tenellone H (5).
This benzophenone exhibited cytotoxic activity against liver (HepG-2; IC50 16 µM) and
lung (A549; IC50 17.6 µM) cancer cell lines [13]. At the even deeper depth of 5752 m,
the trimeric peniphenylanes A and B and dimeric peniphenylanes C–G were reported
from Penicillium fellutanum HDN14-323 isolated from that deep-sea sediment. Of these
seven compounds, only peniphenylane D (6) exhibited reasonable cytotoxic activity against
the cervical cancer cell (HeLa; IC50 = 9.3 µM) [14].
1.3. Seas near China
Moving further East, several cytotoxic agents have been reported from fungi from
deep-sea sediment collected in the South China Sea. For example, the cytotoxic agent
acaromycin A (7) along with acaromyester A were isolated from Acaromyces ingoilii FS121
collected from deep-sea sediment at a depth of 3415 m. The naptha-[2,3-b] pyrandione
analog acaromycin A (7) exhibited cytotoxic activities against human breast (MCF-7), brain
(SF-268), liver (HepG-2), and lung (NCI-H460) cancer cells with IC50 values less than
10 µM [15].
At a deeper depth of 3739 m, engyodontiumones A–J and 2-methoxyl-cordyol C
were isolated from Engyodontium album DFFSCS02. Engyodontiumone H (8) exhibited
cytotoxic activity against human histiocytic lymphoma U937 cells (IC50 = 4.9 µM) together
with antibacterial activity against Escherichia coli and Bacillus subtilis at a concentration of
25 µg/disc (which is low activity for a disc diffusion assay). Engyodontiumin A (9), isolated
from the same fungus, exhibited antimicrobial activities against Aspergillus niger, multidrugresistant Staphylococcus aureus, Vibrio vulnificus, V. rotiferianus, and V. campbellii [16].
1.4. Eastern Pacific Ocean
Several new breviane spiroditerpenoids, breviones F–I, were isolated from a deep
ocean sediment-derived Penicillium sp. (MCCC 3A00005) collected in the East Pacific Ocean
at a depth of 5115 m [17]. Brevione F (10) inhibited HIV-1 replication in C8166 cells with an
EC50 value of 14.7 µM. Breviones F–H (10–12) exhibited minimal cytotoxic activity against
HeLa cells (25 to 50% growth inhibition at 10 µg/mL). Finally, from these agents, brevione
I (13) was cytotoxic against the breast cancer line MCF-7 (IC50 = 7.44 µM) but barely active
against the lung cancer A549 cell line (IC50 = 32.5 µM) [18].
A series of sorbicillinoid derivatives, trisorbicillinone A–D, oxosorbiquinol, dihydrooxosorbiquinol, dihydrodemethylsorbicillin, dihydrotrichodermolide, and phialofurone, were
isolated from the deep ocean fungus Phialocephala sp. Fl30 r collected from sediment at
5059 m in the East Pacific Ocean [19–21]. Of these agents, only trisorbicillinone A (14) exhibited any significant cytotoxic activity against the HL60 tumor cell line (IC50 = 3.14 µM) [19].
Oxosorbiquinol (15) and its dihydro derivative (16) were marginally to effectively inactive
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μM) [19]. Oxosorbiquinol (15) and its dihydro derivative (16) were marginally to effec
tively inactive as cytotoxins against the following tumor cell lines; leukemia (P388, HL60
and K562) and the hepatocellular BEL7402 cell lines with IC50 values from 8.9 to 68.2 μM
as cytotoxins against the following tumor cell lines; leukemia (P388, HL60, and K562) and
respectively [19]. By contrast, dihydrodemethylsorbicillin (17), dihydrotrichodermolide
the hepatocellular (18),
BEL7402
cell lines with IC50 values
from 8.9 to 68.2 µM, respectively [19].
and phialofurone (19, Figure
1) exhibited cytotoxic activity against the leukemia cel
By contrast, dihydrodemethylsorbicillin
(17),
dihydrotrichodermolide
(18),
lines (P388 and K562) with IC50 values ranging from 0.1 to 22.9
μMand
[21].phialo-

furone (19, Figure 1) exhibited cytotoxic activity against the leukemia cell lines (P388 and
K562) with IC50 values ranging from 0.1 to 22.9 µM [21].

Antitumor
Active Agents
Ocean Areas}
(Structures
1 to 19).
Figure 1. AntitumorFigure
Active1. Agents
{Multiple
Ocean{Multiple
Areas} (Structures
1 to
19).

2. Anti-Infective Agents from Deep-Sea Fungi
2.1. South Atlantic Ocean
Marine fungi are also abundant sources of anti-infectives, including potential antifungal, antibacterial, antiprotozoal, and antiviral agents. For example, 19 thiodiketopiperazine
alkaloids, eutypellazines A–S, were isolated from the marine-derived fungus Eutypella sp.
MCCC 3A00281 collected at a depth of 5610 m in the South Atlantic Ocean [22,23]. Eutypellazines A–L (20–31) exhibited anti-HIV activity against pNL4.3Env-Luc co-transfected
293T cells with IC50 values ranging from 3.2 to 18.2 µM. Eutypellazines P–S (32–35, Figure 2)
inhibited the growth of S. aureus ATCC 25923 and vancomycin-resistant Enterococci with
MIC values ranging from 16 to 32 µM [22,23].
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The alkaloids
arthpyrones D–K were isolated from Arthrinium sp. UJNMF0008 collected from the South China Sea at a depth of 3858 m. Of these eight, four, arthpyrones F–
lected from the I South
Seaantibacterial
at a depth
of 3858
m. Mycobacterium
Of these eight,
four,and
arthpy(36–39),China
exhibited
activity
against
smegmatis
S. aureus
rones F–I (36–39),
exhibited
antibacterial
activity
against
Mycobacterium
smegmatis
and
with IC50 values ranging from 1.66 to 42.8 μM [24]. From the deep-sea fungus, P. brevicomDFFSCS025,
isolated
from
sediment
collected
at
3928
m
depth
in
the
South
China
S. aureus with ICpactum
values
ranging
from
1.66
to
42.8
µM
[24].
From
the
deep-sea
fun50
Sea, twoDFFSCS025,
alkaloids, breviamides
and sediment
Y, and two collected
mycochromenic
acid
gus, P. brevicompactum
isolated Xfrom
at 3928
mderivatives,
depth in 6the South China(methyl
Sea, two3-methylbutanoate)-7-hydroxy-5-methoxy-4-methylphthalan-1-one
alkaloids, breviamides X and Y, and two mycochromenic(40)
acidand
derivatives, 6-(methyl 3-methylbutanoate)-7-hydroxy-5-methoxy-4-methylphthalan-1-one
(40) and (30 S)-(E)-7-hydroxy-5-methoxy-4-methyl-6-(2-(2-methyl-5-oxotetrahydrofuran-2yl)vinyl) isobenzofuran-1(3H)-one, were purified. Of these four, only compound 40 exhibited significant antifouling activity against the bryozoan Bugula neritina with an EC50 value
of 13.7 µM and an LC50 /EC50 value > 100 [25].
A small series of compounds were isolated from fermentation of the fungus Emericella sp.
SCSIO 05240, collected from sediment at a depth of 3258 m in the South China sea. These
were four new prenylxanthones, named as emerixanthones A–D. These four agents structurally differ by chlorination, methylation, and hydroxylation, and of the four congeners,
two, emerixanthones A (41) and C (42), exhibited weak antibacterial activity against
several bacterial pathogens, including E. coli, Klebsiella pneumonia, S. aureus, E. faecalis,
Acinetobacter baumanni, and Aeromonas hydrophilia. Interestingly, one of the remaining
two compounds, emerixanthone D (43), exhibited mild antifungal activity against several
agricultural pathogens, including Fusarium sp., Penicillium sp., A. niger, Rhizoctonia solani,
Fusarium oxysporium f. sp. niveum, and F. oxysporium f. sp. cucumeris [26].
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2.3. Indian Ocean
From sediment collected in the Indian Ocean at a depth of 3972 m, the versicoloids
A and B as well as two 4-aryl-quinolin-2-one alkaloids and prenylated xanthones, versicones A–D, were isolated from culturing the fungus A. versicolor SCSIO 05879. Of these
four compounds, only versicoloids A and B (44, 45) demonstrated activity against the plant
pathogen Colletotrichum acutatum (MIC 1.6 µg/mL) [27].
2.4. West Pacific Ocean

Mar. Drugs 2022, 20, x

From sediment collected at a depth of 2869 m in the West Pacific Ocean, the fungus
A. versicolor was isolated and upon fermentation produced the anthraquinone antimicrobial
agent 2-(dimethoxymethyl)-1-hydroxyanthracene-9,10-dione (46, Figure 3). This compound
exhibited antibacterial activity against multidrug-resistant strains of S. aureus ATCC 43300
(MIC 3.9 µg/mL) and CGMCC 1.12409 (MIC 7.8 µg/mL). In addition, it was also weakly
7 of 31 studies with
active against strains of Vibrio (MICs of 15.6–62.5 µg/mL). Molecular docking
topoisomerase IV and AmpC β-lactamase further supported its antibacterial properties [28].
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For example, the diketopiperazine alkaloids brevicompanines D–H were isolated from a
For example, the diketopiperazine alkaloids brevicompanines D–H were isolated from a
deep ocean-sediment isolate of Penicillium sp. collected at a depth of 5080 m. Of these five
deep ocean-sediment isolate of Penicillium sp. collected at a depth of 5080 m. Of these five
compounds, only brevicompanines E (47) and H (48) inhibited lipopolysaccharide-incompounds,
only production
brevicompanines
E (47)
and
H (48) inhibited lipopolysaccharide-induced
duced
nitrous oxide
in microglial
cells
[29].

nitrous oxide production in microglial cells [29].

3.2. Antarctica
Another strain of Penicillium, P. granulatum MCCC 3A00475, isolated from deep-sea
sediment collected at a depth of 2284 m from Prydz Bay in Antarctica yielded the antiallergic spirotetracyclic diterpene, spirograterpene A (49, Figure 4). This compound demonstrated a weak antiallergic activity on immunoglobulin E-mediated rat mast RBL-2H3
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fungal isolate. Pinazaphilone B (52) and 60 -methyl-[1,10 -biphenyl]-3,30 ,40 ,5-tetraol (53) inhibited α-glucosidase with IC50 values of 28.0 and 2.2 µM, respectively, demonstrating
their potential as antidiabetic agents [37].
The She group has reported several metabolites produced by endophytic Talaromyces.
In 2011, they reported cytotoxic norsesquiterpene peroxides produced by an endophytic
T. flavus isolated from the leaves of the mangrove plant Sonneratia apetala collected along
the saltmarsh of the South China Sea [38]. Talaperoxides A to D (54–57), constituted
two isomeric pairs exhibiting toxicity to brine shrimp at median lethal doses (LD50 ) of
less than 10 ppm. These compounds were also evaluated for cytotoxicity against human
breast (MCF-7 and MDA-MB-435), hepatoma (HepG2), cervical (HeLa), and prostate (PC-3)
cancer cell lines. Talaperoxides B (55) and D (57) were cytotoxic against these cell lines
with IC50 values ranging from 0.89 to 1.92 µg/mL. The group later reported two new
benzophenone derivatives, peniphenone and methylpeniphenone, from the mycelia of
an endophytic Penicillium sp. ZJ-SY2 isolated from the same plant [39]. Peniphenone (58)
exhibited immunosuppressive activity against T-cell (concanavalin A-induced) and B-cell
(liposaccharide-induced) proliferation in mouse splenic lymphocytes with IC50 values
of 8.1 and 9.3 µg/mL, respectively. The methyl ester methylpeniphenone (59) exhibited
weaker activity against T cells and B cells with IC50 values of 17.5 and 23.7 µg/mL, respectively. More recently, the group reported two new depsidones, talaromyones A and
B, produced by cultures of Talaromyces stipitatus SK-4 isolated from the leaves of the mangrove plant Acanthus ilicifolius from the Shankou Mangrove Nature Reserve in China. The
acetylated depsidone talaromyone B (60) exhibited antibacterial activity against B. subtilis
(MIC = 12.5 µg/mL) as well as α-glucosidase activity (IC50 = 48.4 µM) [40].
Over the last decade, reports on the number of mangrove-derived strains of Talaromyces
that produce bioactive metabolites have increased, especially as taxonomic revisions have
been made to species with symmetrical biverticillate conidiophores. For more information
on secondary metabolites from mangrove-associated strains of Talaromyces, the 2018 review
by Nicoletti et al. in Marine Drugs is an excellent source of information [41].
Other research groups have reported bioactive compounds from fungal endophytes
isolated from mangrove-associated medicinal plants. For example, Lin and coworkers
published a paper in Phytochemistry describing four new polyketides produced by endophytic Penicillium sp. JP-1 isolated from the inner bark of Aegiceras corniculatum collected
in Fujian, China [42]. A. corniculatum is a shrub known for its analgesic, cytotoxic, and antidiabetic properties [43,44]. Leptosphaerone C, penicillenone, arugosin I, and 9-demethyl
FR-901235 isolated from fungal endophytes of this plant were evaluated for cytotoxic
activity against human lung cancer (A-549) and murine lymphocytic leukemia (P388) cell
lines. Leptosphaerone C (61) exhibited cytotoxic activity against human lung cancer cells
(A-549; IC50 1.45 µM) while penicillenone (62) was cytotoxic against murine lymphocytic
leukemia (P388; IC50 = 1.38 µM).
In 2012, the Wang group published a communication reporting a new cytotoxic and antifungal metabolite, chaetoglobosin X (63) from an endophytic fungus isolated from the leaves
of Curcuma wenyujin Y.H. Chen et C. Ling, which belongs to the ginger family, collected in
Zhejiang Province, Wenzhou, China [45]. Chaetoglobosin X (63) exhibited antifungal activity
against several plant pathogens, including Exerohilum turcicum, F. oxysporum f. sp. Cucumerinim,
Curvularia lunata (MIC; 3.125 µg/mL), as well as F. graminearum and F. moniliforme (MIC;
6.25 µg/mL). Other chaetoglobosins have been reported from the mangrove endophytic
fungus P. chrysogenum V11 isolated from the vein of the medicinal plant Myoporum bonitioides A.
Gray in the Leizhou Penninsula in China [46]. These included penochalasin I (64), containing an unprecedented six-membered fused ring system, and penochalasin J (65). Penochalasin I (65) exhibited cytotoxic activity against gastric (SGC-7901) and breast cancer cell lines
(MDA-MB-435) with IC50 values below 10 µM. Penochalasin J (65) exhibited antifungal
activity against the plant pathogen Colletotrichum gloeosporioides with an MIC of 25.08 µM,
which was more active than the known antifungal agent carbendazim. Other antifungal

Mar. Drugs 2022, 20, 62

9 of 28

agents have been reported from endophytic fungi from this plant. These agents can be
found in the following reports by Li et al. [47–49].
5. Preclinical and Clinical Trials of Mangrove Endophytic-Sourced Compounds
Secondary metabolites isolated from mangrove fungi have entered preclinical and clinical trials. One metabolite was isolated along with a number of cytotoxic anthracenedione
derivatives from the mangrove endophytic fungus Halorosellina sp. no 1403 collected from
the South China Sea. This compound, the anthroquinone SZ-685C (66), was reported by the
She group and demonstrated in vitro and in vivo cytotoxic activity [50]. This agent is structurally similar to the clinically used anticancer drug epiadriamycin and exhibited cytotoxic
activity against human breast cancer (MCF-7, IC50 7.5 µM; MDA-MB-435, IC50 3.0 µM),
prostate cancer (PC-3 cell line, IC50 4.1 µM), glioblastoma (LN-444, IC50 7.8 µM), and hepatoma (Hep-3B, IC50 = 3.2 µM; Huh-7, IC50 = 9.6 µM) cell lines. Importantly, SZ-685C (66)
exhibited low cytotoxic activity against healthy epithelial cells [50], and increased sensitivity towards the invasive and estrogen-independent breast cancer cell lines, which are more
resistant to anti-estrogen therapy. Thus, SZ-685C (66) may be a promising treatment for
adriamycin-resistant breast cancer, and a patent was filed in 2010 [51]. Xenograft studies
in which mice inoculated with MDA-MB-435 cells were dosed with 50 mg/kg of SZ-685C
(66) showed a significant decrease of 61% in tumor volume after 35 days of drug administration. SZ-685C (66) was later found to selectively induce apoptosis in malignant cells
in vitro and in vivo via the inhibition of the Akt pathway, which helps cancer cells survive
apoptosis [52].
Additional in vitro assays and mechanistic studies have been published on SZ-685C (66).
In 2013, Chen and coworkers reported inhibition of pituitary adenoma, specifically rat
prolactinoma (MMQ) cells, and normal rat pituitary cells (RPCs) with IC50 values of
13.2 mM and 49.1 mM, respectively [53]. The apoptotic activity of SZ-685C in the pituitary
adenoma cells resulted from the downregulation of miR-200c, a microRNA implicated in
regulating tumorigenesis and commonly upregulated in various tumors. It also inhibited
MMQ cells, lowering their miR-200c levels in a dose-dependent manner and exhibited less
toxicity toward RPCs. SZ-685C (66) was also reported to inhibit human nasopharyngeal
carcinoma (CNE2; IC50 = 8.97 µM) and its radioresistant analog (CNE2R; IC50 =8.94 µM)
cell lines after only 72 h of treatment [54]. In 2015, SZ-685C (66) was also reported to
exhibit cytotoxic activity against non-functioning pituitary adenoma, a benign growth, by
upregulating caspase-3 and phosphate and tensin (PTEN) homolog and decreasing Akt
expression levels [55]. The lack of selectivity between CNE2 and CNE2R is notable, as
radioresistance is a major challenge for naso-pharyngeal carcinoma patients and has been
linked to the activation of several pro-apoptotic signaling pathways. Significant decreases
in miR-205 expression levels were observed in CNE2R cells incubated with SZ-685C (66),
inactivating the miR-205-PTEN-Akt and Stat3-Jab1-p27 pathways. Thus, SZ-685C (66)
could also be a promising treatment for nasopharyngeal carcinoma patients. To date, there
have been no additional reports on (pre)-clinical studies on this compound.
6. Plinabulin Clinical Trials
Aside from SZ-685C (66), the only other marine-derived fungal metabolite in the
clinical trials pipeline is the cytotoxic agent plinabulin (NPI-2358; 67), a synthetic derivative
of the diketopiperazine halimide (68). Halimide (68) is produced by Aspergillus sp. CNC139 isolated from the green alga Halimeda copiosa collected from the coast of the Philippine
Islands as part of studies funded under an NIH Cooperative grant system known as the
NCDDG (National Cooperative Drug Discovery Group). These grants involved both
academia and the pharmaceutical industry, with in this case, NIH/NCI involvement. The
NCDDG consortium that discovered halimide (68) was led by the Fenical group at the
Scripps Oceanographic Institution in La Jolla California, with a report covering their initial
results published in 2000 [56]. Fenical and Jensen set up the small company Nereus to
further develop agents from the NCDDG and other microbial sources. Some of the earlier
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7. Bioactive Compounds from Fungi Isolated from Marine Vertebrates and
Selected Invertebrates
In addition to mangrove plants, marine fungi have mutualistic interactions with
other organisms, including marine vertebrates, animals with backbones including fish,
amphibians, mammals, reptiles, and birds. These animals have commensal, competitive,
and predatory interactions with each other. For example, mammals find food by following
birds and birds take advantage of the herding efforts of predatory fishes and mammals
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for food. Furthermore, these animals are active and mobile, covering wide distances to
avoid competitors, reducing the rate of evolutionary divergence. Yet, their mobility also
provides opportunities to obtain nutrients from different locations, increasing the diversity
of their microbiomes.
From initial sequencing studies, the microbiomes of some mammals and marine vertebrates were found, as expected, to have gut microbiota diversity across species [59–62].
Several fish microbiomes have been sequenced and found to be unique environmental
niches for the microbial production of new bioactive molecules [63]. While fish are the
most dominant marine vertebrates, only a small number of natural products have so far
been reported from these organisms. Fumiquinazolines A–G (69–75) were produced by
the fungus A. fumigatus isolated from the gastrointestinal tract of the Japanese saltwater
fish Pseudolabrus japonicas [64,65]. These peptidyl alkaloids have variable degrees of oxygenation, methylation, and substitution on their indole moieties and all exhibited cytotoxic
activity against the murine lymphocytic leukemia (P388) cells with ED50 values of 6.1, 16.0,
14.6, 17.7, 52.0, 13.5 and 13.8 µg/mL, respectively.
This next section might seem out of place, but we have put it here due to the similarity in the structures that were isolated, as this demonstrates that the “nominal host” is
perhaps not the controlling factor. The structurally related fumiquinazolines H–L were
isolated from fermentation of an Acremonium sp. obtained from the non-vertebrate marine tunicate Ecteinascidia turbinata [66], as well as other marine-derived A. fumigatus and
endophytic Scopulariopsis sp. isolated from non-vertebrate gorgonians [67]. Some of these
fumiquinazolines inhibited the proliferation of mouse CDC2-mutant (tsFT210) cells, including compounds 69, 71, and 74 from the fish-related fungus and fumiquinazoline J
(78, Figure 6) from the tunicate, while fumiquinazolines H–I (76, 77) exhibited antifungal
activity. The 2019 review by Resende et al. [68] is an excellent discussion on the fumiquinazolines, covering their source(s), chemical and biological activities. This review along
with the 2020 article in Marine Drugs by Han et al. [69] should be consulted for current
13 of 31
information on this class of fungal metabolites and relatives, including genomic aspects
underlying their production.
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8. Further Piscine-Sourced Agents
A single fungal strain, Chaetomium globosum OUPS-T106B-6 isolated from the marine
fish Mugil cephalus collected in Katsuura Bay, Japan led to the discovery of several cytotoxic polyketides. Two groups led by Tanaka [70,71], reported six new cytotoxic azaphi-
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Due to the duplication of structures and names related to fumiquinazolines published
from different sources, with approximately 80 mentioned in the Resende et al. review [68],
we have used the structures for fumiquinazoline A to J from that source, rather than those
first reported in 1992 [64].
8. Further Piscine-Sourced Agents
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A single fungal strain, Chaetomium globosum OUPS-T106B-6 isolated from the marine
fish Mugil cephalus collected in Katsuura Bay, Japan led to the discovery of several cytotoxic
polyketides. Two groups led by Tanaka [70,71], reported six new cytotoxic azaphilones, the
chaetomugilins A–F (79–84), that differed in their degrees of hydroxylation and methylation.
All compounds exhibited cytotoxic activity against murine leukemia (P388) and human
promyelocytic leukemia (HL-60) cell lines with IC50 values ranging from 1.3 to 18.7 µM.
The bioactivity of chaetomugilins C (81) and F (84) indicate that the hydroxyl and methoxy
groups at C-12 and C-30 contribute to their cytotoxicity. Furthermore, chaetomugilins
A (79), C (81), and F (84) exhibited selective cytotoxic activity against 39 human cancer
cell lines, implying that their modes of action were different from any other anticancer
drug developed at the time of publication. Chaetomugilins G–H (85–86), azaphilones with
hydrolyzed lactone rings, were also reported by the authors from the same fungal strain [72].
Both compounds exhibited growth inhibitory activity against murine lymphocytic leukemia
(P388 and L1210) as well as human promyelocytic leukemia (HL-60) and epidermoid
carcinoma (KB) cells with IC50 values ranging from reasonably active (10.3 µM) to effectively
inactive (137.8 µM) for pure compounds.
The same research group later reported chaetomugilins I–O, which had either a fivemembered ether ring or various oxygenation and methylation patterns, from the same
fungal strain [73]. Chaetomugilin I (87) also exhibited select cytotoxic activity against the
same 39 human cancer cell lines mentioned above. Chaetomuglin J (88) was also recently
reported to enhance apoptosis induced by cisplatin in human ovarian cancer cells, increas14 of 31
ing their sensitivity to cisplatin by decreasing mitochondrial membrane potentials and
increasing reactive oxygen species levels [74]. Derivatives in which the lactone moiety was
hydrolyzed, seco-chaetomugilins A and D (89), were also found in the culture broth of
hydrolyzed, seco-chaetomugilins A and D (89), were also found in the culture broth of the
the same fungal isolate [75]. The lack of the C-12 hydroxyl group in seco-chaetomugilin
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single-celled organisms which are the potential actual sources of the secondary metabolites
isolated from the host invertebrate. Several cytotoxic metabolites have been reported from
fungal strains isolated from sponges.
A new cyclohexapeptide (similanamide, 91) was isolated from cultures of the spongeassociated Aspergillus similanensis KUFA0013. The strain was isolated from the marine
sponge Rhadbermia sp. collected from the coral reef of the Similan Islands in Thailand at
a depth of 10 m [78]. Similanamide (91) exhibited weak activity against breast adenocarcinoma (MCF-7), non-small-cell lung cancer (NCI-H460), and melanoma cell lines with
GI50 values ranging from 115 to 125 µg/mL [79]. In 2015, Masuda et al. [80] published a
revision of the structure confirmed by total synthesis, identifying it as one of the two cyclic
peptides reported in 2010 by Kai et al. Both peptides resulted from a cofermentation of
the unidentified ascomycete OK-128 with okara, and exhibited paralytic activity against
silkworms [81].
Seven new polyketides were isolated from Alternaria sp. SCIO41014 collected from the
sponge Callyspongia sp. collected near Xuwen County, Guangdong Province, China. One of
the isolated perylenequinone derivatives, 4,8,10-trihydroxy-1,2,11,12-tetrahydroperylene-3quinone (also named Altertoxin VII, 92), exhibited cytotoxic activity against a wide range
of cancer cells, including human erythroleukemia (K562), human gastric carcinoma cells
(SGC-7901), and hepatocellular carcinoma cells (BEL-7402) with IC50 values of 26.58 ± 0.80,
8.57 ± 0.13 and 13.11 ± 0.95 ug/mL, respectively [82].
New sorbicillinoid derivatives have been reported from a fungus isolated from the
fresh internal tissue of a sponge collected from the South China Sea. Trichoreeseiones
A–B, trichodermolide B, 13-hydroxy-trichodermolide, 24-hydroxy-trichodimerol (93), and
15-hydroxy-bisvertinol were isolated from Trichoderma reesei (HN-2016-018). Notably,
24-hydroxy-trichodimerol exhibited cytotoxic activity against lung (A549), breast (MCF-7),
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and liver (HCT-116) cancer cell lines with IC50 values of 5.1, 9.5, and 13.7 µM, respectively [83].
Crabs and sea cucumbers have also been a source of bioactive fungal secondary metabolites. The cyclic depsipeptides clavatustides A–B (94–95) were isolated from Aspergillus clavatus
C2WU isolated from the crab Xenograpsus testudinatus from the hydrothermal vent Kueishantao in Taiwan [84]. Both compounds inhibited HepG2 liver cancer cell growth in the
G1/S phase transition. An antimicrobial agent, cladomarine (96), was isolated from a
sea-cucumber-derived fungus Penicillium coralligerum YK-247 collected at a depth of 3064 m
on the Sao Paulo Plateau off the coast of Brazil. Cladomarine (96, Figure 8) exhibited
16 of 31
antimicrobial activity in disc diffusion assays against the pathogens Saprolegnia
parasitica
and Pythium sp. sakari1 at a concentration of 10 µg per disc [85].
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A variety of techniques have been used to activate these BGCs, including chromatin
remodeling, leading to the opening of the cell’s chromatin to enable gene transcription.
10.
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aureus with an MIC value of 8 μg/mL. Other compounds have also been produced by a
single strain grown in media containing an HDAC or DNA methyltransferase inhibitor.
For example, 5-azacytidine was added to cultures of mangrove-derived P. variabile HXQH-1 and reported to produce a new fatty acid amide varitatin A (98) [94]. This fatty acid
amide demonstrated cytotoxicity against colon carcinoma (HCT-116) cells with an IC50
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transcription, including methylation, phosphorylation, acetylation, ubiquitination, and
sumoylation. As such, chemical epigenetic modifiers, such as Zn2+ -type histone deacetylase
(HDAC) and DNA methyltransferase inhibitors, have been added to fermentation media
and successfully stimulated the expression of cryptic BGCs [92].
Several studies have reported the induction of cryptic metabolites by supplementing
media with chemical epigenetic modifying agents. The HDAC inhibitor suberohydroxamic
acid (SBHA) induced the production of a new biphenyl derivative versiperol A (97) in the
fermentation of A. versicolor MCCC 3A00080, which was isolated from deep-sea sediment
(2721 m deep) in the Pacific Ocean [93]. Versiperol A inhibited the growth of S. aureus
with an MIC value of 8 µg/mL. Other compounds have also been produced by a single
strain grown in media containing an HDAC or DNA methyltransferase inhibitor. For
example, 5-azacytidine was added to cultures of mangrove-derived P. variabile HXQ-H-1
and reported to produce a new fatty acid amide varitatin A (98) [94]. This fatty acid amide
demonstrated cytotoxicity against colon carcinoma (HCT-116) cells with an IC50 value of
2.8 µM. It also inhibited protein tyrosine kinases, such as PDGFR-β and ErbB4 kinases with
inhibitory rates of 50% and 40%, respectively, at a concentration of 1 µM. When the same
strain was cultivated in the presence of the HDAC inhibitor suberoylanilide hydroxamic
acid (SAHA), four new compounds, varilactones A and B, and wortmannilactones M and N
were produced [95]. None of these compounds exhibited cytotoxic activity or antiviral activity against the influenza A (H1N1) virus. However, this is a great example of how structural
diversity can be accessed in a single strain via the addition of epigenetic modifiers.
Many compounds exhibiting non-cytotoxic or non-infective bioactivities have been
reported from deep-sea fungi grown in the presence of DNA or HDAC inhibitors. Readers
should consult the work of Wang et al. [96], Beau et al. [97], and Zhang et al. [98] for details
of the new fungal metabolites induced by the addition of DNA and HDAC inhibitors.
11. OSMAC
One strain–many compounds (OSMAC) is another successful approach used to elicit
the production of cryptic metabolites. This is actually a renaming of a very old system
used initially by antibiotic researchers in the pharmaceutical industry, but never formally
published as such. As an example, one of the authors (DJN) was using this technique as a
laboratory assistant in the UK in the late 1950s. Since all industrial researchers knew what
was used as media components by colleagues in other pharmaceutical and/or agrichemical
houses due to frequent personnel movement between companies, there was no need for
any formal paper. This also applied up through the 1980s in industry as well.
The first “formal academic publication” discussing these multiple media techniques
was published by Zahner in 1979 though it was based on a lecture in 1977 [99]. In addition,
in 1982, a book covering the methods for search and discovery of bioactive microbial
products was published by the UK “Society for General Microbiology” that included a
relevant article by Zahner, based on his earlier publications, but the essential point was that
of the three editors, two were from the UK pharmaceutical industry who were involved in
the active search for novel antibiotics, whilst the third editor was at the Microbial Chemistry
laboratory at the University of Manchester [100]. This book was not well known outside of
UK and EU microbial researchers, but the essential point is that it preceded the “nominal
OSMAC” story by 20 years. The current term for this old technique “OSMAC” came from a
paper in 2002 by Bode et al. [2], but no attribution was given to Zahner’s earlier published
work which was known in German academic circles.
With all microbes, including fungi, the methods involve a systematic modification of
cultivation conditions to trigger cryptic gene clusters, as microbial metabolomics change in
response to stress stimuli (e.g., pH, temperature, and the addition of metals, antibiotics,
and flavonoids) [101]. In addition to varying cultivation parameters, fermentation media
can also be supplemented with precursors and enzyme inhibitors [102]. This approach
has successfully induced several compounds in marine fungal cultures, especially in
Spicaria elegans KLA03 CCTCC M 205049. For example, Lin and coworkers reported the
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production of new cytochalasins, aspochalasins (M–Q), and spicochalasin A (99) when
S. elegans from marine sediment in Jiaozhou Bay, China was cultivated on 2% starch as the
sole carbon source [103]. Spicochalasin A (99) with an unusual pentacyclic system, exhibited
cytotoxic activity against human leukemic (HL-60) cells with an IC50 value of 19.9 µM. A
revised structure was published by a different group under the name flavichalasine D in
2021, with structure (99) being the revised version [104]. Interestingly, the same gene cluster
that produced spicochalasin A produced nine new cytochalasins, when grown on glucose,
demonstrating the effects primary metabolism can have on secondary metabolism [105,106].
Simply varying salinity has induced the production of structurally diverse fungal
metabolites. The endophytic Nigrospora sp. MA75 isolated from the marine semi-mangrove
plant Pongamia pinnata was found to produce a mixed polyketide-terpenoid, 2,3-didehydro19α-hydroxy-14-epicochlioquinone B (100), when cultivated in media containing 3.5%
NaCl [107]. Two new griseofulvin derivatives, 6-O-desmethyldechlorogriseofulvin and
60 -hydroxy-griseofulvin, were also isolated when the same strain was cultured on solid rice
medium. In addition to antibacterial activity, compound 100 exhibited cytotoxic activities
against human breast cancer (MCF-7), pancreatic cancer (SW1990), and hepatocellular
cancer (SMMC7721) cell lines with IC50 values of 4, 5, and 7 µg/mL, respectively [107].
When Aspergillus sp. SCSIO F063 isolated from a deep-sea sediment in the South
China Sea was cultured in potato dextrose broth supplemented with 3% sea salt, seven new
chlorinated anthraquinones were produced. (10 S)-7-Chloroaverantin, (10 S)-6-O-methyl7-chloroaverantin (101), (10 S)-10 -O-methyl-7-chloroaverantin, (10 S)-6,10 -O,O-dimethyl-7chloroaverantin, (10 S)-7-chloroaverantin-10 -butyl ether, 7-chloroaverythrin, and 6-O-methyl7-chloroaverythrin are anthraquinones with a chlorine atom at C-7 as well as different
methoxy, n-butyl, and unsaturated alkyl chain groups [108]. Two new brominated compounds were produced when the culture broth of the same strain was supplemented
with 3% sodium bromide. Of all of the new metabolites produced, only 6-O-methyl7-chloroaverantin (101) exhibited strong cytotoxic activity against human glioblastoma
(SF-268), breast cancer (MCF-7), and lung cancer (NCI-H460) cell lines with IC50 values of
7.11, 6.64, and 7.42 µM, respectively.
When grown in media containing 10% saline, S. elegans KLA03 isolated from a marine sediment in Jiaozhou Bay, China produced (2E,20 Z)-3,30 -(6,60 -dihydroxybiphenyl-3,30 diyl)diacrylic acid (102) [109]. Compound 102 exhibited antibacterial activity against
Pseudomonas aeruginosa and E. coli with MIC values of 0.038 mM and 0.767 mM, respectively.
When Luan et al. grew the same strain in a mannitol-based medium using ammonium
chloride as the nitrogen source, it produced a small amount of a rare, unstable, highly
oxygenated spiro[isobenzofuran-1,30 -isochroman] ring system, eleganketal A (103), which
could not be evaluated for bioactivity, but the structure was confirmed by synthesis of the
permethylated derivative [110].
Thus, simply modifying salinity and/or the halide ion can produce a variety of bioactive agents hopefully providing enough material that can be isolated for biological evaluation, or alternatively the agent might be synthesized. As examples of varying the halide, a
new radical scavenging brominated isocoumarin, (R)-(–)-5-bromomellein (104) was also produced once sodium bromide was added to the fermentation broth of the fungus A. ochraceus
isolated from the marine red alga Chondria crassicualis collected in Korea [111]. Compound
(104) exhibited radical scavenging activity against 1,1-diphenyl-2-picrylhydrazyl radical
2,2-diphenyl-1-(2,4,6-trinitrophenyl) hydrazyl (DPPH) with an IC50 value of 24 µM, which
was comparable to the L-ascorbic acid positive control (IC50 = 20 µM).
Supplementing the fermentation broth with amino acids can produce amino acid
derivatives, again a technique known from many years earlier as “precursor-directed
biosynthesis”. Wang and coworkers used this strategy to obtain new cytochalasins from an
S. elegans KLA03 strain. Three new cytochalasins, cytochalasins Z21 (105), Z22 (106), and
Z23 were produced when cultures were supplemented with L- and D-tryptophan [112]. Cytochalasins are derived from acetate, a methionine-derived octa- or nonaketide chain, and
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an amino acid. Notably, cytochalasins Z21 (105) and Z22 (106) exhibited cytotoxic activity
against human lung adenocarcinoma (A-549) with IC50 values of 8.2 and 20.0 µM, respectively.
The addition of L-tryptophan and L-phenylalanine to the fermentation broth of
Dichotomomyces cejpii F31-1 isolated from the soft coral Lobophytum crassum collected in
the South China Sea has also led to the production of several new compounds [113].
Four amides, dichotomocejs A (107) to D, one polyketide dichocetide A, and two diketopiperazines dichocerazines A–B were produced. Dichotomocej A (107) exhibited weak
activity against the human rhabdomyosarcoma cell line RD with an IC50 value of 39.1 µM.
The other dichotomocejs were not evaluated but it would be interesting to see how the
differing structural substitutions might have altered their biological activity.
Metals have been added to fermentation broths to induce the production of new
metabolites. Free metals can function as a “chemical switch” and upregulate biosynthetic
pathways or they can be used in either dissimilatory or assimilatory reactions. Some organisms, such as hydrothermal vent microorganisms, are particularly sensitive to changes in
the concentrations of available metals, such as copper, and produce new metabolites, many
of which have not been assessed for bioactivity [114–116]. Wang et al. [117], reported that
Ascotricha sp. ZJ-M-5 isolated from coastal mud in Fenghua County, Zhejiang Province,
China produced new caryophyllene derivatives, (+)-6-O-demethylpestalotiopsin A (108),
(+)-6-O-demethyl-pestalotiopsin C (109), and (-)-6-O-demethylpestalotiopsin B, when cultivated in Czapek Dox broth with or without Mg2+ . This is the first time caryophyllene
derivatives have been detected in Ascotricha cultures. (+)-6-O-Demethylpestalotiopsin A
(108) and (+)-6-O-demethyl-pestalotiopsin C (109, Figure 9) exhibited growth inhibitory
activity against human promyelocytic leukemia (HL-60; GI50 = 6.9 and 8.5 µM) and human
chronic myelogenous leukemia (K562; GI50 = 10.1 and 12.3 µM) cell lines.
Switching from liquid to solid media can also trigger the production of new metabolites. For example, nine new C9 polyketides were produced by the hydrothermal ventderived Aspergillus sp. 16-02-1 (Lau Basin hydrothermal vent, southwest Pacific at 2255 m
and 114 ◦ C) when grown on rice [118], as opposed to a liquid medium, which only produced
known compounds [119]. When re-fermented on solid substrate, aspiketolactonol (110),
aspilactonols A–F (though E and F are an unseparated mixture of epimers) (111–115), aspyronol (116), epiaspinonediol (117), and five new ambuic acid derivatives were produced.
Compounds 110–115 are α,β-unsaturated γ-lactones with varying degrees of oxygenation, whereas compound 116 is an α,β-unsaturated δ-lactone ring and compound 117
is a branched, acyclic C8 carbon chain with a conjugated diene moiety. All compounds
(110–117) inhibited human leukemia and gastric cancer cell lines (K562, HL-60, and BGC823 cells) to varying degrees. Aspyronol (116) and epiaspinonediol (117) were more potent
and selective cytotoxic agents on human leukemia (K562 and HL-60) cell lines.
When Guo and coworkers switched from growing a deep-sea-derived Penicillium sp.
F23-2 (from a Chinese deep ocean sediment at 5080 m) in complex liquid media to a
rice-based solid medium [120], penicyclones A–E (118–122) were produced. This strain
was already reported to produce meleagrins, roquefortines, and terpenoids in a potatobased medium under static conditions and sorbicillinoids in peptone yeast glucose broth
medium with agitation. Penicyclones A–E (118–122) differ in their degrees of oxygenation,
unsaturation, and alkyl chain length. Yet, all compounds exhibited antimicrobial activity
against S. aureus with MIC values ranging from 0.3 to 1.0 µg/mL.
Simple changes in fermentation vessels can also improve yields and reduce processing times. For example, the yields of the antibiotics ascosetin (123) and lindgomycin (124,
Figure 10) from an Arctic-sourced Lindgomycetaceae isolated from the sponge Halichondria panicea,
improved by a factor of 100 once transferred from an Erlenmeyer flask to a stirred tank
reactor [121].

Mar. Drugs 2022, 20, 62

tiopsin A (108), (+)-6-O-demethyl-pestalotiopsin C (109), and (-)-6-O-demethylpestalotiopsin B, when cultivated in Czapek Dox broth with or without Mg2+. This is the first time
caryophyllene derivatives have been detected in Ascotricha cultures. (+)-6-O-Demethylpestalotiopsin A (108) and (+)-6-O-demethyl-pestalotiopsin C (109, Figure 9) exhibited
growth inhibitory activity against human promyelocytic leukemia (HL-60; GI50 = 6.9 and
18 of 28
8.5 μM) and human chronic myelogenous leukemia (K562; GI50 = 10.1 and 12.3 μM) cell
lines.

Figure9.9.Modification
Modificationof
of Media
Media Components/Fermentation
Components/Fermentation Conditions
I (Structures
97–109).
Figure
Conditions
I (Structures
97–109).

Switching fromcues,
liquidsuch
to solid
media can alsocan
trigger
the the
production
of new
metaboEnvironmental
as temperature,
trigger
expression
of silent
gene
lites. For
example,
nine new
C9 polyketides
produced
by the from
hydrothermal
ventclusters.
Liu
and coworkers
reported
five newwere
polyketides
produced
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JH-18
isolated from coastal marine soil from Bohai Bay, China once the fermentation temperature
was lowered from 28 ◦ C to 15 ◦ C [122]. The change in the temperature significantly altered
the P. raistrickii JH-18 metabolome and new raistrickione diastereomers, raistrickiones A–C
(125–127), and analogs, raistrickiones D and E (128–129), were produced. Raistrickiones
A–E exhibited radical scavenging activity against DPPH with IC50 values of 32, 38, 40, 49,
and 42 µM, respectively. The IC50 value of the ascorbic acid positive control was 17 µM. It
would be interesting to know the optimal growth temperature of this Penicillium strain to
understand why these metabolites are produced.
Supplementing culture media with enzyme inhibitors has also led to the production
of new bioactive compounds. For example, based on several species of Phomopsis and
Chaetomium sp. producing well-known actin depolymerizers (i.e., chaetoglobosins), the
Crews group added an actin inhibitor to induce the production of unprecedented chaetoglobosins. Three new chaetoglobosins with various levels of oxygenation, chaetoglobosin-510,
-540, and -542 (130), were produced when the actin inhibitor jasplakinolide (aka jaspamide)
was added to cultures of Phomopsis asparagi isolated from the sponge Rhaphidophlus juniperina
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based solid medium [120], penicyclones A–E (118–122) were produced. This strain was
already reported to produce meleagrins, roquefortines, and terpenoids in a potato-based
medium under static conditions and sorbicillinoids in peptone yeast glucose broth medium with agitation. Penicyclones A–E (118–122) differ in their degrees of oxygenation,
unsaturation, and alkyl chain length. Yet, all compounds exhibited antimicrobial activity
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Other enzyme inhibitors, such as the P-450 dependent monooxygenase inhibitor
metyrapone, have been used to induce the production of new metabolites [124]. For more
information on the application of these well-known principles to marine fungi, see the
reviews by Reen et al. [125] and Romano et al. [126].
12. Optimization of Growth Conditions and Strains for Large-Scale Production
A common problem in finding new bioactive fungal metabolites is not having enough
isolated material for biological evaluation. However, metabolite production can be further
optimized by modifying growth conditions. For example, altering the salinity has also
improved the yields of the antibiotics obioninene (131) as well as corollosporine (132)
and derivatives (in the presence of laccase treatment) produced by driftwood-derived
Leptosphaeria oraemaris [127], and Corollospora maritime [128,129]. Time is also an important
factor that has been found to influence the accumulation or depletion of metabolites, with
several studies reporting the impact of time on activating hidden metabolomes [130].
Several variables can be modified at once to optimize the yields of isolated fungal
metabolites. For example, in optimized medium, cultivation time of three days, and
28 ◦ C growth temperature, the yield of the antibacterial, lipodepsipeptide 15G256γ (133)
produced by mangrove-derived Hypoxylon oceanicum LL-15G256 (Shenzen, China) increased
from ~50 to 400 mg/L [131]. In addition, simple modifications in pH and growth time
were also shown to be important for producing optimal amounts of the antibacterial
exophilin A (134), which was produced by Exophilia pisciphila isolated from the sponge
Mycale adhaerans [132]. Furthermore, spore inoculation, low agitation (50 rpm) and pH
(4.5), an aeration rate of 0.33 vvm, and a 2-fold amount of maltose and glucose on the
sixth day of growth in cultures of A. terreus PF-26 (isolated from the sponge Phakellia fusca)
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grown in a stirred 5-L reactor led to a 1.65-fold increase in (+)-terrein, (135) a cytotoxic
antibiotic to 2.68 g/L) [133]. While these modifications have been successful, using the
“one-factor-at-a-time” approach can be time-consuming and does not reveal the interactions
of various parameters.
Controlled and targeted methods, involving statistical analyses, can modify multiple
variables simultaneously. Alternative methodologies, including orthogonal array designs,
Plackett–Burman, and response surface methodologies (RSM), have been developed to
optimize product yields by examining the effects of multiple variables in parallel in a
minimal set of experiments.
Genichi Taguchi developed the orthogonal array design, a statistical method that
determines how different parameters affect product yields in the smallest number of
experiments, without having to explore all possible combinations [134]. Though somewhat
“dated” this strategy provides the significant and optimal contributions of each variable.
The Plackett–Burman experimental design, though originally published in 1946, measures the dependence of a measured quantity on various complex media components
in a way that minimizes the variance of these dependencies using a limited number of
experiments [135]. This technique was utilized extensively in the earlier days of antibiotic
production when companies wished to reduce the sizes of their production fermentors.
RSM is another sequential technique that involves designing experiments, mathematical models, and statistical analyses to explore relationships between a response variable and
a set of design variables [136]. This approach determines influential factors and how they
interact with each other, revealing the role of each component in the optimization process.
Orthogonal array designs, Plackett–Burman designs, and RSM were all used to increase the yield of the antineoplastic compound aspergiolide A (136) from the marinederived A. glaucus HB1-19 by 4.22-fold (71.2 mg/L) [137,138]. RSM was also used to
optimize the antineoplastic, antibiotic penicilazaphilone C (137) produced by the marinederived fungus P. sclerotiorum M-22, first reported by Zhou et al. in 2016 [139], and then
optimized increasing the yield by 1.344-fold [140].
DNA modifications and genetic engineering have also been used to coerce fungal
strains into producing higher yields. For example, ultraviolet radiation was used to mutate
the DNA of Scopulariopsis brevicaulis LF580 to optimize the yield of the sponge-derived
scopularide A (138) [141]. This cyclic peptide whose structure was revised in 2016 [142],
exhibited cytotoxic activity against pancreatic and colon tumor cells [143,144]. In this
optimization work, a faster-growing UV-mutated strain (LF580-M26) that rapidly produced
more scopularide A was identified. The LF580-M26 strain showed differences in pellet
formation, which is relevant as proteomics revealed the wild-type strain’s limited nutrient
availability due to its robust pellet formation.
Genetic engineering has also improved metabolite yields by (in)activating genomic
segments via the manipulation of regulators or chromatin-modifying enzymes. Scopularide
A (138, Figure 11) was optimally produced by S. brevicaulis LF580 once its biosynthetic gene
Mar. Drugs 2022,
20, x
cluster
was identified [145]. The following papers and reviews give more information on 23
producing bioactive fungal metabolites via genetic engineering [91,146,147].
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Chaichanan and coworkers grew Xylaria sp. Acra L38 in sucrose, maltose, glucose, and
Chaichanan and coworkers grew Xylaria sp. Acra L38 in sucrose, maltose, glucose, and
sodium nitrate and increased the zofimarin yield 8-fold compared to when it was grown
sodium nitrate and increased the zofimarin yield 8-fold compared to when it was grown in
Czapek yeast extract. Many of the natural products discussed here, especially those that
are mangrove-derived, may also be produced by terrestrial fungi, which could be explored
for greater product supplies.
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